Earn points on every order New products in stock Free 51-page beginner’s guide
← Back to Compound Library

Melanotan I (MT-1)

Triggers a tan. FDA-approved as Scenesse for a rare condition where sunlight is painful. More selective and safer than MT-2.

Research referenceCommunity compiled

Molecular profile

The molecule itself: sequence, composition, mass, target, and registry identifiers.

Molecular formula
C₇₈H₁₁₁N₂₁O₁₉
Average mass
1646.8 Da
CAS number
75921-69-6
Registry
PubChem CID 16197727
Receptor / pathway
MC1R
Formula, mass and identifiers from PubChem CID 16197727.
Research & reference information

This profile compiles research and community-sourced reference information for educational purposes. Information may evolve as research and community knowledge develop. It is not individualized medical advice.

Overview

Melanotan I (Afamelanotide / MT-1) is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH) engineered for photoprotection and natural skin tanning.

What problem it targets: It targets sun hypersensitivity, phototoxicity (such as erythropoietic protoporphyria / EPP), severe sunburn risk in fair skin, and lack of natural protective melanin.

What It Does

• Selectively activates melanocortin 1 receptors (MC1R): Binds MC1R on skin melanocytes, stimulating the natural synthesis of photoprotective eumelanin pigment.

• Provides natural internal UV protection: Deepens natural skin pigmentation, creating a protective melanin shield that absorbs and deflects UV rays, drastically cutting sunburn risk.

• Exceptional receptor selectivity: Unlike Melanotan II, MT-1 has minimal binding to MC3R and MC4R, avoiding central side effects like nausea, facial flushing, and spontaneous sexual arousal.

• Realistic expectations: Requires gradual dosing over several weeks paired with minimal UV light exposure to build a natural, sun-protective tan that persists for months.

Reconstitution

Vial sizeBAC water / SolventConcentration
10 mg+ 2 mL5 mg/mL

Protocol

PhaseFrequencyDoseNotes
Loading (Weeks2×/week250Loading cadence, 500 mcg/week total. Pair with daily 15–30 min UV exposure to build baseline melanin. Slower-
1–4)SubQmcg
Maintenance1×/week250Maintenance cadence, 250 mcg/week total (half the loading rate). Sustains pigmentation with continued UV
(Weeks 5+)SubQmcg
OffWith UV–As desired. MT-1 has a cleaner side-effect profile than MT-2 (no nausea, libido changes, or appetite suppression). cycle Cycle: 4 weeks loading + ongoing maintenance with seasonal UV. Cleanest results with consistent UV exposure during the loading phase. Timing: Daily during loading, then maintenance 2–3×/week. Evidence: not approved; afamelanotide is the only approved α-MSH analog. Reviews flag melanoma/mole risk. By sex: Melanocortin effects hit both sexes: skin and mole darkening (melanoma monitoring), nausea, appetite drop. Same MC1R pathway in men and women.

Handling & Stacking

Injection site
SubQ abdomen or outer thigh.
Storage
  • Freeze-dried: -4°F.
  • Reconstituted: 36–46°F.
  • Best used within 28 days, otherwise potency gradually fades over ~4–6 weeks (structure-based estimate, no published data).
  • Protect from light.
Side effects
Nausea (lower than MT-2), flushing, hyperpigmentation.
What to expect
Tan builds over 2–4 wks (melanin up within days); less nausea than MT-2. Baseline skin check first. Supply math 10mg → 1 vial (5-wk @ 250 mcg × 2/wk)
Pairs well with
Vitamin D (offsets some pigmentation cofactor demand)
Avoid
Personal or family history of melanoma. Active dysplastic naevi (mole monitoring required)

Safety & Patient Education

Contraindications
Personal or family history of melanoma Atypical mole syndrome / dysplastic nevus syndrome Active skin cancer or pre-malignant skin lesions Uncontrolled hypertension Cardiovascular disease (significant) Pregnancy and lactation
Warnings
Hyperpigmentation of all melanocytes including existing moles, mole monitoring required New mole formation Transient BP elevation (PT-141: mean ~6 mmHg systolic per FDA Vyleesi label) Nausea, especially MT-2 during loading Priapism risk in men (MT-2 specifically) Spontaneous erections (MT-2) Reduced response and tachyphylaxis with frequent use More selective for MC1R; less nausea, less libido effect, less BP impact than MT-2; same melanoma surveillance still applies
Drug interactions
PDE5 inhibitors (sildenafil, tadalafil, vardenafil): additive BP effects with PT-141; separate timing per label Antihypertensives: additive or paradoxical BP effects Vasoactive drugs in general
Labs
Dermatology mole mapping (photo-documented) at baseline + ABCDE recheck every 12 weeks on-cycle, then every 6–12 months Blood pressure log at baseline and before each dose
Stop criteria
New atypical mole or rapid change in existing mole (ABCDE criteria) Sustained BP elevation above 140/90 in previously normotensive patient Priapism (sustained erection more than 4 hours): seek emergency care Severe nausea not resolving with dose reduction
Patient education
Use sunscreen during MT-1/MT-2, extra melanin doesn’t replace UV protection Photograph moles at baseline; recheck monthly ABCDE warning signs: Asymmetry, Border irregularity, Color variation, Diameter >6mm, Evolution MT-2: erections are pharmacologic, >4 hours is a medical emergency PT-141: do not exceed 1 dose per 24 hours
References
researchdosing · peptidedosages · DailyMed · PubMed · ClinicalTrials · Drugs.com · Dorr 1996